120 related articles for article (PubMed ID: 11430449)
21. Risedronate increases bone mineral density and reduces the vertebral fracture incidence in postmenopausal women.
Reginster JY
Clin Exp Rheumatol; 2001; 19(2):121-2. PubMed ID: 11326471
[No Abstract] [Full Text] [Related]
22. The effect of risedronate on the risk of hip fracture in elderly women.
Royce PC
N Engl J Med; 2001 May; 344(22):1720; author reply 1721. PubMed ID: 11386283
[No Abstract] [Full Text] [Related]
23. [Faster and long-lasting protection with risedronate. With strengthened bones longer self-sufficient].
MMW Fortschr Med; 2004 May; 146(22):52-3. PubMed ID: 15373118
[No Abstract] [Full Text] [Related]
24. [Osteoporosis: diagnosis, prevention and treatment].
Baranauskaite A; Savickiene A
Medicina (Kaunas); 2002; 38(2):234-9; quiz 240. PubMed ID: 12474746
[TBL] [Abstract][Full Text] [Related]
25. RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction.
Curtis JR; Westfall AO; Cheng H; Saag KG; Delzell E
Osteoporos Int; 2009 Jun; 20(6):973-8. PubMed ID: 18946630
[TBL] [Abstract][Full Text] [Related]
26. Alendronate (Fosamax) and risedronate (Actonel) revisited.
Obstet Gynecol; 2005 Aug; 106(2):402-4. PubMed ID: 16055597
[No Abstract] [Full Text] [Related]
27. The effect of risedronate on the risk of hip fracture in elderly women.
Goodman RL
N Engl J Med; 2001 May; 344(22):1720-1. PubMed ID: 11386282
[No Abstract] [Full Text] [Related]
28. The effect of risedronate on the risk of hip fracture in elderly women.
Schott AM; Dargent-Molina P; Meunier PJ
N Engl J Med; 2001 May; 344(22):1721. PubMed ID: 11386284
[No Abstract] [Full Text] [Related]
29. [Effect of anti-osteoporosis agents on the incidence of vertebral fractures].
Lems WF; Dijkmans BA
Ned Tijdschr Geneeskd; 2000 Oct; 144(41):1941-5. PubMed ID: 11048556
[TBL] [Abstract][Full Text] [Related]
30. [Bisphosphonate treatment prevents hip fractures in 70-79 year old women with osteoporotic vertebral fractures].
Netelenbos JC
Ned Tijdschr Geneeskd; 2001 Jul; 145(28):1336-8. PubMed ID: 11484428
[TBL] [Abstract][Full Text] [Related]
31. Osteoporosis drugs in real-world clinical practice: an analysis of persistence.
Iolascon G; Gimigliano F; Orlando V; Capaldo A; Di Somma C; Menditto E
Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S137-41. PubMed ID: 24046038
[TBL] [Abstract][Full Text] [Related]
32. Hip fractures: do preventive drugs work for all?
Health News; 2001 Mar; 7(3):7. PubMed ID: 11263091
[No Abstract] [Full Text] [Related]
33. Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body.
Chevalier Y; Quek E; Borah B; Gross G; Stewart J; Lang T; Zysset P
Bone; 2010 Jan; 46(1):41-8. PubMed ID: 19800436
[TBL] [Abstract][Full Text] [Related]
34. Absolute vs. relative numbers in evaluating drug therapy.
McCormack J
Am Fam Physician; 2001 May; 63(10):1913-4, 1916. PubMed ID: 11388707
[No Abstract] [Full Text] [Related]
35. [New guideline for the treatment of osteoporosis].
Matsumoto T
Nihon Rinsho; 2004 Feb; 62 Suppl 2():387-91. PubMed ID: 15035157
[No Abstract] [Full Text] [Related]
36. Drugs for prevention and treatment of postmenopausal osteoporosis.
Med Lett Drugs Ther; 2000 Oct; 42(1090):97-100. PubMed ID: 11035622
[No Abstract] [Full Text] [Related]
37. Changes in bone resorption markers among Japanese patients with postmenopausal osteoporosis treated with alendronate and risedronate.
Takada J; Iba K; Imoto K; Yamashita T
J Bone Miner Metab; 2007; 25(2):142-6. PubMed ID: 17323185
[TBL] [Abstract][Full Text] [Related]
38. An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae.
Lanza F; Schwartz H; Sahba B; Malaty HM; Musliner T; Reyes R; Quan H; Graham DY
Am J Gastroenterol; 2000 Nov; 95(11):3112-7. PubMed ID: 11095326
[TBL] [Abstract][Full Text] [Related]
39. Clinical trial of risedronate in Japanese volunteers: single and multiple oral dose studies.
Ogura Y; Gonsho A; Cyong JC; Orimo H
J Bone Miner Metab; 2004; 22(2):111-9. PubMed ID: 14999521
[TBL] [Abstract][Full Text] [Related]
40. Once-a-week alendronate (Fosamax).
Med Lett Drugs Ther; 2001 Mar; 43(1100):26. PubMed ID: 11257718
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
